Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche sees diagnostic sales soar after acquisition:

This article was originally published in Clinica

Executive Summary

Roche's diagnostic division had sales of SwFr4.6 billion ($3.3 billion) in 1998, reflecting the Swiss company's acquisition of Boehringer Mannheim in mid-1997. In the previous year, Roche's diagnostic sales were SwFr966 million. Roche says its PCR-based products and patient care division both had double-digit sales growth, its molecular biochemicals division had substantial growth, while its laboratory systems sales were "down sightly in a saturated market". Roche's total sales were SwFr24,660 million, up 31%. The figures do not include turnover for the orthopaedics company DePuy, in which Roche had a majority holding and which was sold to Johnson & Johnson in July 1998.

You may also be interested in...



Financing Quarterly Statistics, Q1 2024

During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.

Helping Organizations Deliver On KPIs And Giving Staff A Voice

ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT077275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel